Compare Stocks

Date Range: 

 FONARIRIDEXBioSig TechnologiesENDRA Life SciencesSoleno Therapeutics
SymbolNASDAQ:FONRNASDAQ:IRIXNASDAQ:BSGMNASDAQ:NDRANASDAQ:SLNO
Price Information
Current Price$17.19$7.80$3.21$2.17$1.11
52 Week RangeN/ABuyN/AN/ABuy
MarketRank™
Overall Score1.10.90.50.61.9
Analysis Score0.01.50.00.03.5
Community Score2.82.52.72.32.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.02.5
Earnings & Valuation Score1.90.60.00.60.6
Analyst Ratings
Consensus RecommendationN/ABuyN/AN/ABuy
Consensus Price TargetN/A$6.50N/AN/A$8.67
% Upside from Price TargetN/A-16.67% downsideN/AN/A680.78% upside
Trade Information
Market Cap$112.66 million$121.88 million$103.18 million$90.36 million$88.49 million
Beta1.071.21.831.60.71
Average Volume34,812332,111312,4332,705,9551,586,255
Sales & Book Value
Annual Revenue$85.69 million$43.45 millionN/A$10,000.00N/A
Price / Sales1.312.81N/A9,035.88N/A
Cashflow$1.82 per shareN/AN/AN/AN/A
Price / Cash9.44N/AN/AN/AN/A
Book Value$19.58 per share$1.65 per share$0.53 per share$0.57 per share$0.33 per share
Price / Book0.884.73N/A3.81N/A
Profitability
Net Income$8.24 million$-8,810,000.00$-34,060,000.00$-13,310,000.00$-30,770,000.00
EPSN/A($0.64)N/A($2.34)($0.70)
Trailing P/E Ratio16.22N/A0.00N/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins8.28%-21.54%N/AN/AN/A
Return on Equity (ROE)5.57%-38.60%-244.64%-492.76%-88.69%
Return on Assets (ROA)3.99%-24.99%-213.88%-288.58%-51.63%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%0.06%N/A0.10%N/A
Current Ratio5.32%2.77%6.83%3.42%7.06%
Quick Ratio5.22%2.01%6.67%3.19%7.06%
Ownership Information
Institutional Ownership Percentage62.09%32.61%18.33%2.84%55.38%
Insider Ownership Percentage8.58%2.00%19.49%9.60%74.90%
Miscellaneous
Employees42489491817
Shares Outstanding6.55 million15.63 million32.14 million41.64 million79.72 million
Next Earnings Date5/10/2021 (Estimated)5/11/2021 (Confirmed)5/10/2021 (Estimated)5/17/2021 (Confirmed)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Soleno Therapeutics (NASDAQ:SLNO) Releases  Earnings Results, Misses Estimates By $0.03 EPSSoleno Therapeutics (NASDAQ:SLNO) Releases Earnings Results, Misses Estimates By $0.03 EPS
americanbankingnews.com - May 6 at 9:48 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Down Almost -13.93% in 1 Month, But Long Term Looking GoodSoleno Therapeutics, Inc. (NASDAQ:SLNO) Down Almost -13.93% in 1 Month, But Long Term Looking Good
marketingsentinel.com - May 6 at 1:19 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Expected to Post Earnings of -$0.04 Per ShareSoleno Therapeutics, Inc. (NASDAQ:SLNO) Expected to Post Earnings of -$0.04 Per Share
americanbankingnews.com - May 5 at 11:12 PM
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 5 at 5:18 PM
Soleno Therapeutics DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome PatientsSoleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients
finance.yahoo.com - May 4 at 3:38 PM
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi SyndromeSoleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
finance.yahoo.com - May 4 at 10:37 AM
After A 5.13% Rise In The Last Week, Does Soleno Therapeutics, Inc. (NASDAQ:SLNO) Still Make Sense To Buy?After A 5.13% Rise In The Last Week, Does Soleno Therapeutics, Inc. (NASDAQ:SLNO) Still Make Sense To Buy?
marketingsentinel.com - April 30 at 2:57 PM
Critical Review: Micron Solutions (OTCMKTS:MICR) vs. Soleno Therapeutics (NASDAQ:SLNO)Critical Review: Micron Solutions (OTCMKTS:MICR) vs. Soleno Therapeutics (NASDAQ:SLNO)
americanbankingnews.com - April 30 at 4:30 AM
Soleno Therapeutics, Inc. (NASDAQ:SLNO): Here’s What’s Really Going OnSoleno Therapeutics, Inc. (NASDAQ:SLNO): Here’s What’s Really Going On
stocksregister.com - April 28 at 2:13 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Expected to Announce Earnings of -$0.04 Per ShareSoleno Therapeutics, Inc. (NASDAQ:SLNO) Expected to Announce Earnings of -$0.04 Per Share
americanbankingnews.com - April 18 at 6:18 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Sees Significant Increase in Short InterestSoleno Therapeutics, Inc. (NASDAQ:SLNO) Sees Significant Increase in Short Interest
americanbankingnews.com - April 18 at 4:44 AM
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town HallSoleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
finance.yahoo.com - April 15 at 12:21 AM
Soleno Therapeutics, Inc. (SLNO) has great growth outlook for 2021Soleno Therapeutics, Inc. (SLNO) has great growth outlook for 2021
marketingsentinel.com - April 12 at 3:02 PM
Soleno Therapeutics (SLNO) Enters Oversold TerritorySoleno Therapeutics (SLNO) Enters Oversold Territory
finance.yahoo.com - March 30 at 9:01 AM
Heres Why Were Watching Soleno Therapeutics (NASDAQ:SLNO) Cash Burn SituationHere's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
finance.yahoo.com - March 29 at 5:55 PM
Market Analysts see Soleno Therapeutics Inc. [SLNO] gaining to $8. Time to buy?Market Analysts see Soleno Therapeutics Inc. [SLNO] gaining to $8. Time to buy?
dbtnews.com - March 26 at 6:34 PM
SLNO Jul 2021 4.000 callSLNO Jul 2021 4.000 call
au.finance.yahoo.com - March 13 at 9:23 AM
Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference Nasdaq:SLNOSoleno to Participate in the 31st Annual Oppenheimer Healthcare Conference Nasdaq:SLNO
compsmag.com - March 9 at 5:38 PM
Soleno to Participate in the 31st Annual Oppenheimer Healthcare ConferenceSoleno to Participate in the 31st Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 9 at 5:38 PM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the FirmBronstein, Gewirtz & Grossman, LLC Announces Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the Firm
finance.yahoo.com - March 9 at 12:38 PM
Soleno Therapeutics (SLNO) Is in Oversold Territory: Whats Next?Soleno Therapeutics (SLNO) Is in Oversold Territory: What's Next?
msn.com - March 9 at 7:38 AM
Why Soleno Therapeutics Is Trading Lower TodayWhy Soleno Therapeutics Is Trading Lower Today
msn.com - March 8 at 12:51 PM
Soleno Shares Are Trading Lower After FDA Demands Additional Study For DCCR Program In Prader-Willi SyndromeSoleno Shares Are Trading Lower After FDA Demands Additional Study For DCCR Program In Prader-Willi Syndrome
finance.yahoo.com - March 8 at 12:51 PM
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results - 03.03.2021Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results - 03.03.2021
wallstreet-online.de - March 5 at 8:17 AM
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 ...Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 ...
apnews.com - March 4 at 7:13 AM
DateCompanyBrokerageAction
3/9/2021IRIDEXRoth CapitalBoost Price Target
5/12/2020IRIDEXStifel NicolausLower Price Target
2/20/2019BioSig TechnologiesLaidlawSet Price Target
11/18/2019ENDRA Life SciencesHC WainwrightReiterated Rating
6/13/2019ENDRA Life SciencesDougherty & CoInitiated Coverage
5/20/2019ENDRA Life SciencesLake Street CapitalInitiated Coverage
3/3/2021Soleno TherapeuticsOppenheimerReiterated Rating
9/29/2020Soleno TherapeuticsGuggenheimInitiated Coverage
1/10/2020Soleno TherapeuticsCraig HallumInitiated Coverage
12/20/2018Soleno TherapeuticsMaxim GroupSet Price Target
5/16/2018Soleno TherapeuticsNoble FinancialSet Price Target
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.